Key Takeaways
- Margin squeeze from inventory lag, not demand collapse: Gross margin fell sharply because 100-day high-cost inventory was sold into falling API prices, creating a ~₹30 cr revenue impact and a ₹6 cr inventory write-down. Management calls it a conscious, temporary trade-off to hold market share.
- The worst is declared over: Management states the worst is behind, citing a pickup in chronic and acute therapies and improving volume off-take from January 2023.
- Specialty Chemicals doubling in sight: Customer commitments received for brownfield expansion products support a target to double Specialty Chemicals revenue in 12 months, with a longer-term aim of 20–25% of standalone revenue.
- Capex on track, revenue potential framed: Tarapur greenfield (dermatology APIs) and Gujarat capex are on schedule; once all expansions complete, total revenue potential is pegged at ~₹4,500 cr with an 18% EBITDA margin target.
- What to watch next quarter: Whether the promised Q4 gross margin recovery materializes as low-cost inventory flows through, and whether API prices stabilize after January’s further decline.
Margin Mechanics: The Inventory Lag
- The core problem: Raw material takes 15–30 days to reach the factory, then sits in ~100 days of inventory. When finished product prices fell significantly in the December quarter, sales were fulfilled using raw material purchased at September-quarter elevated rates, squeezing gross margins.
- Quantified impact: If December inventory had been purchased at September rates, it would have cost ₹33 cr higher; at June rates, ₹45 cr higher. The rate variance between September purchase rates and December selling rates caused a ~₹30 cr revenue impact.
- Inventory write-down: A ₹6 cr loss was booked on finished goods where cost price exceeded selling price, marking inventory down to net realizable value.
- Conscious strategy: Management deliberately maintained full production scale to avoid losing market share to competitors, accepting the temporary margin decline as a trade-off against the uncertainty of production losses and client defection.
- The Q4 recovery bet: Low-cost raw material inventory will be utilized from Q4 FY23 onwards, which is expected to improve gross margins, provided prices do not fall further. January saw a further price reduction versus the December quarter average, but if the decline stops, margins at the order level remain decent.
Adhish Patil: "We took a conscious call but we don't want that means temporarily decline in margins is okay, but then the production should be at full scale. So that we don't lose any market share. And the natural downside of that was squeeze in the gross margin."
Demand & Pricing Environment
- API price correction: Industry-wide API prices corrected mainly due to falling raw material prices. The company undertook price cuts to maintain market share. Government prices are now almost at pre-COVID levels or lower.
- Volume under pressure: Export volume saw slight de-growth due to higher API prices and US dollar unavailability in emerging markets. Domestic volume was flattish with marginal 2–3% growth. Standalone 6% YoY growth was entirely pricing-driven, not volume-driven.
- Demand recovery signal: Management is witnessing improvement in volume off-take from January 2023 onwards and expects volume to return to a growth trajectory within two to three months. Pipeline inventory has come down to a very realistic level.
- Export receivables stable: December quarter credit days for exports were in line with previous averages, and the company has taken insurance on export receivables for added comfort.
Harit Shah: "As far as government prices are concerned, they are almost at pre-COVID level or lower than that. And as far as demand is concerned, we expect demand to pick up in the next two or three months, February, March onwards. We expect demand to further move up. So all inventory, which were in pipeline has come down to a very realistic level now."
Specialty Chemicals: The Growth Engine
- Revenue doubling target: With committed customer orders received for brownfield expansion products and a campaign-based product, management states it can easily double Specialty Chemicals revenue in the next 12 months from existing brownfield facilities alone.
- Longer-term mix shift: The company aims to take Specialty Chemicals and intermediates to around 20–25% of standalone revenue after two to three years, up from its current smaller base.
- Capacity ramp-up timing: The brownfield chloro-sulphonation expansion is currently operating at just 10% utilization, waiting for one equipment expected to arrive in April 2023. Once installed, production can scale up immediately.
- Greenfield to follow: A greenfield capex for Specialty Chemicals will drive further growth in upcoming years, beyond the brownfield doubling.
- China share gain: The company received a 30% bump in a particular contract manufacturing order for a specialty chemical product, gaining market share from China.
Capex Pipeline & Revenue Ambition
- Tarapur greenfield (dermatology APIs): Construction expected to complete by end of Q1 FY24. The facility will mainly produce import-substitute dermatology-related APIs. Scale-up batches are already being taken at another location.
- Gujarat capex: Construction activity was ramped up and is expected to finish within the scheduled timeline.
- Total revenue potential: Once brownfield, greenfield, and antidiabetic expansions are all complete, revenue potential can reach ~₹4,500 cr, including both new capex and existing capacity utilization. All expansions to be completed by end of FY24 in the worst case.
- Funding approach: The company will optimally use a mix of debt and internal accruals to fund ongoing capex, while striving to maintain shareholder payouts.
- Scale-up readiness: Management states the company is well prepared to take up scale-up batches immediately once construction is ready.
Segment Dynamics
| Segment | Trend | Commentary |
|---|---|---|
| API | ▲ 9% YoY revenue growth | Driven by increased share of chronic and acute therapies. |
| Formulation | ▼ 9% YoY decline | Decline is technical: product manufactured for a Latin American tender was shipped to the subsidiary as an internal sale. Revenue will be recognized in the March quarter when sold to the final authorities in that country. |
| Specialty Chemicals | ▲ Growth driver | Expected to grow at a higher pace than API, supported by brownfield expansion commitments and a greenfield pipeline. |
- API margin recovery path: Once the input price scenario stabilizes, management sees at least 3–4% improvement in gross margins visible from monthly sales versus purchase order contracts. The 34% gross margin level is achievable in APIs as well when stabilization occurs.
- Competitive positioning: In the top 15 products manufactured, the company's capacities are as big as or bigger than Chinese competitors, enabling it to market products at par with China. The company has penetrated Southeast Asian markets over 6–7 years and already exports 3–4 products to China, with more being added.
Adhish Patil: "The products in which we are there, because the fact that our capacities are as big as Chinese, if not bigger than them in many of the cases, in the top 15 products which we manufacture, that is the reason why we are able to market our products at par with China."
Regulatory & Market Access
- US FDA status: The final response to the US FDA was furnished in September. Clearing the import alert would fully open the European market from that facility, as some multinationals currently refrain from procuring because their product goes to both US and EU markets.
- EDQM audit: A fresh EDQM audit was completed in October for the same plant under US FDA import alert. Canadian authorities subsequently cancelled their scheduled January audit because EDQM had already inspected the plant recently. An Australian audit also took place last year.
- Formulation tender win: The company won a tender in a Latin American market for formulation. The product was manufactured locally and moved to the subsidiary; revenue recognition will occur in the March quarter.
Adhish Patil: "In some of the multinationals, who are procuring APIs in their formulation plant for both US as well as European market, they refrain procuring from us because their product is going to both the markets, and we are approved only for Europe and not for US. So that is challenging sometimes. ... if we clear US FDA, then even the Europe market will open up fully for us from that facility."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Gross margin improvement | Low-cost inventory flows through, improving margins provided prices do not fall further | Q4 FY23 onwards |
| Volume recovery | Volume off-take returns to growth trajectory | Within 2–3 months (Feb–Mar 2023) |
| Specialty Chemicals revenue doubling | Double revenue from existing brownfield facilities only | Next 12 months |
| Specialty Chemicals capacity scale-up | Equipment arrives, production scales immediately | April 2023 |
| Tarapur greenfield operational | Construction complete, scale-up batches begin | End of Q1 FY24 (June 2023) |
| All expansions complete | Brownfield + greenfield + antidiabetic | End of FY24 (worst case) |
| Total revenue potential | ~₹4,500 cr including new capex and existing utilization | After all expansions complete |
| EBITDA margin target | ~15–16% at higher utilization; ~18% with higher spec chem and export formulation exposure | After all expansions complete |
| Specialty Chemicals revenue mix | 20–25% of standalone revenue | After 2–3 years |
| Formulation revenue recognition | Latin American tender revenue booked | March quarter (Q4 FY23) |
Key Metrics
| Metric | Q3 FY23 |
|---|---|
| Standalone revenue | ₹614.4 cr, +6% YoY from ₹579.9 cr |
| Consolidated revenue contribution (standalone) | 92% tentatively |
| Domestic revenue growth | +8% YoY |
| Export revenue growth | +2% YoY |
| API segment revenue growth | +9% YoY |
| Formulation segment revenue | ₹49.9 cr, 8% of total revenue |
| Formulation segment revenue growth | -9% YoY |
| Specialty intermediate and others revenue growth (9M FY23) | +15% YoY |
| Gross margin | 34% (per an analyst's math), flat YoY |
| Inventory loss | ₹6 cr, contributing ~1% to gross margin squeeze |
| Total capex (9M FY23) | ₹115 cr |
| Total capex guidance (FY23) | ₹200 cr to ₹250 cr |
| Net debt-to-equity | 0.53x as of December 31, 2022 |
| API therapeutic mix: antibiotic | 45% of API sales |
| API therapeutic mix: antidiabetic | 16% of API sales |
| API therapeutic mix: antiprotozoal | 16% of API sales |
| API therapeutic mix: anti-inflammatory | 12% of API sales |
| API therapeutic mix: antifungal | 8% of API sales |
| Domestic volume growth | +2% to +3% YoY, flattish marginal |
| Export volume growth | Slight de-growth YoY |
| Specialty chemicals revenue share | 4% to 5% of standalone revenue |
| Specialty chemicals and intermediates revenue target | 20% to 25% of standalone revenue in 2–3 years |
| Revenue potential post-expansions | ~₹4,500 cr including brownfield, greenfield, and antidiabetic facility |
| EBITDA margin target (current business, higher utilization) | 15% to 16% |
| EBITDA margin target (post all expansions) | Towards 18% |
| Raw material inventory days | ~100 days at start of December quarter |